Vascular Biogenics Ltd (VBLT)

[gr8db8]

One thing to note is that trial recruiting is done by word-of-mouth in the medical industry - there are FDA restrictions on what a company can do to inform the industry and patients on the trial.

My read into being 5 months ahead of schedule is that

1) The medical community is cautiously optimistic about VB-111. They like what they are seeing so far. Doctors are recommending VB-111 to their rGBM patients; and

2) With the internet and support groups, patients are now more informed. They know about prior trials and they are getting recommendations from other patients, who have had good success with VB-111.

Phase 3 recruiting timeline was based on phases 1 and 2 rates, multiplied by the number of recruiting sites involved. To be 5 months ahead means that there was a huge spike in interest from both the medical and patient communities.